Large New Study Supports Statins For Alzheimer’s Disease

Large New Study Supports Statins For Alzheimer’s Disease; Nymox -NASDAQ: NYMX- Has Global Patent Rights for the Use of Statin Drugs for the Treatment and Prevention of Alzheimer’s Disease

MAYWOOD, N.J.–(BUSINESS WIRE)–April 28, 2004–A large new study has found strong further evidence that statin drugs have therapeutic benefit for Alzheimer’s Disease (AD). Statin drugs are widely used cholesterol-lowering drugs. Researchers from France presented these significant new findings at the American Academy of Neurology meeting this week in San Francisco.

Investigators followed 342 Alzheimer’s disease patients for 35 months to determine whether taking statin and/or fibrates to lower cholesterol would have an effect on their rate of cognitive decline. They found that taking the cholesterol-lowering agents was associated with a slower cognitive decline and suggested that they may have a therapeutic benefit by a mechanism independent from the cholesterol-lowering action. The study, “Effects of Statins and Fibrates on Progression of Cognitive Decline in Alzheimer’s Disease,” was authored by Isabelle Masse, Regis Bordet, Dominique Deplanque, Abdullatif Al Khedr, Christian Libersa, and Florence Pasquier.

Nymox Pharmaceutical Corporation (NASDAQ: NYMX) holds U.S. and global patent rights for the use of statin drugs for the prevention and treatment of AD.

According to Dr. Michael Munzar, Medical Director of Nymox, “Statin drugs have huge potential for Alzheimer’s disease. They are safe, well tolerated and widely available. This large new study again supports the considerable body of evidence showing that taking statin drugs has positive effects on cognition in the elderly and can reduce the risk of Alzheimer’s disease.”

A growing body of scientific and clinical studies have shown the potential benefits of statin drugs to prevent or treat AD. Studies have shown up to 70% reduction in AD incidence in individuals who use statin drugs. Recent studies include, for example, Neuroepidemiology 2004; 23:94-8; Neuron 2004; 41:7-10; Arch Neurol 2000; 57:1439-1443; Lancet 2000; 356:1627-1631; Arch Neurol 2002; 59:223-227; J Gerontol Biol Sci Med Sci 2002;57:M414-M418; and J Am Geriatr Soc 2002;50:1852-1856.

The current global market for statins is estimated at $19 billion per year and to be growing at 15% per year. Alzheimer’s disease is the leading cause of dementia in the elderly, afflicting an estimated 4.5 million people in the U.S.

More information about Nymox is available at, email:, or 800-936-9669.

This press release contains certain “forward-looking statements” as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management’s current expectations. Such factors are detailed from time to time in Nymox’s filings with the United States Securities and Exchange Commission and other regulatory authorities.

1 Star2 Stars3 Stars4 Stars5 Stars (188 votes, average: 3.10 out of 5)

Leave a Reply